At a glance
ClinicalIndex Comparison Record- ✓ECOG performance status 0-1
- ✓Age 18 years or older
- ✓Weight loss less than 10% in the preceding 3 months
- ✓Adjuvant chemotherapy is permitted if completed more than 6 months before protocol entry
- ✕Clinical brain metastases
- ✕Prior chemotherapy for systemic disease
- ✕Imminent need for chemotherapy for impending organ dysfunction
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of Tarceva for Untreated, Good Prognosis Patients With Advanced Non-Small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating Erlotinib (Tarceva) for Lung Cancer. Completed, enrolled 40 participants across 1 site.
Detailed Summary
This study will evaluate Tarceva in a selected population of patients with untreated advanced non-small cell lung cancer who are anticipated to have a relatively good (indolent) prognosis based on clinical criteria. It is anticipated that selection will enrich for tumor characteristic that are likely to be benefited by EGFR inhibitor treatment (survival greater than 90 days). The goal of this strategy is to provide a less toxic, oral treatment for patients with advanced NSCLC that will not interfere with patients receiving chemotherapy at some point in the future and may prolong the time to chemotherapy related progression. Patients will remain on study until disease progresses, a decline in performance status, if patient cannot tolerate the side effects or develops symptoms requiring conventional chemotherapy.
Study Details
Timeline
Interventions
Erlotinib